Molecular pathology and prostate cancer therapeutics: from biology to bedside

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Prostate cancer (PCa) is a common malignancy with heterogeneous behavior, largely driven by androgen signaling.
• Castration-resistant prostate cancer (CRPC) still relies on androgen signaling, necessitating advanced therapeutic strategies.
• Understanding PCa molecular subtypes is key to personalized treatment approaches.

Purpose of the Study:

• To explore the evolving landscape of prostate cancer therapeutics.
• To highlight the role of molecular pathology in patient stratification and treatment selection.
• To discuss the impact of molecular insights on managing prostate cancer.

Main Methods:

• Review of current literature on prostate cancer molecular subtypes and targeted therapies.
• Analysis of genetic alterations in PCa, including ETS gene fusions, SPOP mutations, and SPINK1 overexpression.
• Discussion of therapeutic strategies targeting both cancer cells and the tumor microenvironment.

Main Results:

• PCa exhibits significant molecular heterogeneity, with distinct subtypes like ETS-rearranged, SPOP-mutant, and SPINK1-overexpressing tumors.
• Androgen signaling remains central even in CRPC, driving the development of novel blocking agents.
• Therapies targeting the tumor microenvironment also show promise in prolonging patient survival.

Conclusions:

• Molecular pathology is essential for identifying patients who will benefit from specific targeted therapies.
• Stratifying prostate tumors into distinct molecular entities will enable more precise treatment selection.
• A deeper understanding of PCa molecular biology will empower pathologists to guide clinical management effectively.